TY - JOUR
T1 - Heart Failure
T2 - Exercise-Based Cardiac Rehabilitation: Who, When, and How Intense?
AU - Haykowsky, Mark J.
AU - Daniel, Kathryn M.
AU - Bhella, Paul S.
AU - Sarma, Satyam
AU - Kitzman, Dalane W.
N1 - Publisher Copyright:
© 2016 Canadian Cardiovascular Society
PY - 2016/10
Y1 - 2016/10
N2 - The primary chronic symptom in patients with clinically stable heart failure (HF) is reduced exercise tolerance, measured as decreased peak aerobic power (peak oxygen consumption [VO2]), and is associated with reduced quality of life and survival. Exercise-based cardiac rehabilitation (EBCR) is a safe and effective intervention to improve peak VO2, muscle strength, physical functional performance, and quality of life and is associated with a reduction in overall and HF-specific hospitalization in clinically stable patients with HF. Despite these salient benefits, fewer than one-tenth of eligible patients with HF are referred for EBCR after hospitalization. In this review, selection for and timing of EBCR for patients with HF, as well as exercise prescription guidelines with special emphasis on the optimal exercise training intensity to improve peak Vo2, are discussed.
AB - The primary chronic symptom in patients with clinically stable heart failure (HF) is reduced exercise tolerance, measured as decreased peak aerobic power (peak oxygen consumption [VO2]), and is associated with reduced quality of life and survival. Exercise-based cardiac rehabilitation (EBCR) is a safe and effective intervention to improve peak VO2, muscle strength, physical functional performance, and quality of life and is associated with a reduction in overall and HF-specific hospitalization in clinically stable patients with HF. Despite these salient benefits, fewer than one-tenth of eligible patients with HF are referred for EBCR after hospitalization. In this review, selection for and timing of EBCR for patients with HF, as well as exercise prescription guidelines with special emphasis on the optimal exercise training intensity to improve peak Vo2, are discussed.
UR - http://www.scopus.com/inward/record.url?scp=85014068010&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014068010&partnerID=8YFLogxK
U2 - 10.1016/j.cjca.2016.06.001
DO - 10.1016/j.cjca.2016.06.001
M3 - Review article
C2 - 27692119
AN - SCOPUS:85014068010
SN - 0828-282X
VL - 32
SP - S382-S387
JO - Canadian Journal of Cardiology
JF - Canadian Journal of Cardiology
IS - 10
ER -